Returns–Not enough quarters yet
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| LLYEli Lilly & Co | $46.9M | 6.3% | +88.9% |
| PFEPfizer Inc | $42.7M | 5.7% | +21.0% |
| VEEVVeeva Sys Inc | $42.0M | 5.6% | New |
| BMRNBiomarin Pharmaceutical Inc | $39.0M | 5.2% | New |
| PTCTPtc Therapeutics Inc | $35.4M | 4.7% | +15.3% |
| BAXBaxter Intl Inc | $31.1M | 4.2% | New |
| INSMInsmed Inc | $30.0M | 4.0% | +44.6% |
| ZBHZimmer Biomet Holdings Inc | $27.3M | 3.7% | −45.2% |
| PODDInsulet Corp | $26.9M | 3.6% | New |
| TMOThermo Fisher Scientific Inc | $26.0M | 3.5% | New |
| ABTAbbott Laboratories | $25.9M | 3.5% | New |
| Ascendis Pharma A/sCUSIP K08588103 | $25.3M | 3.4% | New |
| SOLVSolventum Corp | $24.4M | 3.3% | New |
| Medtronic PLCCUSIP G5960L103 | $23.7M | 3.2% | New |
| ELANElanco Animal Health Inc | $21.3M | 2.8% | −7.2% |
| AGIOAgios Pharmaceuticals Inc | $20.3M | 2.7% | New |
| NVSTEnvista Holdings Corporation | $19.1M | 2.6% | New |
| RVMDRevolution Medicines Inc | $15.5M | 2.1% | −73.8% |
| ICUIIcu Med Inc | $15.5M | 2.1% | −58.4% |
| COGTCogent Biosciences Inc | $15.2M | 2.0% | +11.6% |
| LNTHLantheus Hldgs Inc | $14.7M | 2.0% | −46.8% |
| OCULOcular Therapeutix Inc | $14.6M | 2.0% | |
| ELDNEledon Pharmaceuticals Inc | $13.9M | 1.9% | −1.1% |
| TYRATyra Biosciences Inc | $12.0M | 1.6% | New |
| OLMAOlema Pharmaceuticals Inc | $11.6M | 1.5% | −38.5% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| ELDNEledon Pharmaceuticals Inc | December 31, 2025 | +160.9% | $13.9M |
| RVMDRevolution Medicines Inc | December 31, 2025 | +135.1% | $15.5M |
| DNLIDenali Therapeutics Inc | December 31, 2025 | +55.8% | $10.1M |
| LNTHLantheus Hldgs Inc | March 31, 2026 | +46.3% | $14.7M |
| PTCTPtc Therapeutics Inc | March 31, 2026 | +19.7% | $35.4M |
| LLYEli Lilly & Co | December 31, 2025 | +11.6% | $46.9M |
| PACSPacs Group Inc | December 31, 2025 | +11.1% | $9.2M |
| COGTCogent Biosciences Inc | December 31, 2025 | +9.0% | $15.2M |
| ELANElanco Animal Health Inc | December 31, 2025 | +8.7% | $21.3M |
| ICUIIcu Med Inc | December 31, 2025 | +2.8% | $15.5M |
Sold off last quarter
- HSICSchein Henry Inc was $46.0M
- BDXBecton Dickinson & Co was $43.9M
- DXCMDexcom Inc was $33.8M
- ISRGIntuitive Surgical Inc was $31.2M
- NBIXNeurocrine Biosciences Inc was $27.7M
- ITGRInteger Hldgs Corp was $18.7M
- BIIBBiogen Inc was $17.7M
- TNDMTandem Diabetes Care Inc was $14.6M
- Nuvalent IncCUSIP 670703107 was $13.3M
- Ascendis Pharma A/sCUSIP 04351P101 was $11.9M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +8.1% | +14.8% |
| March 31, 2026 | −4.7% | −4.6% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Defilade Capital Management, L.P. Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2088557&type=13F-HR&dateb=&owner=include&count=40CIK 2088557
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/2088557/000208855726000008/Filed August 14, 2026 · accession 0002088557-26-000008